Mitsubishi UFJ Asset Management
FDMT icon

Mitsubishi UFJ Asset Management’s 4D Molecular Therapeutics FDMT Stock Holding History

Mitsubishi UFJ Asset Management’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$354K Buy
26,644
+3,374
+14% +$32.9K ﹤0.01% 935
2026
Q1 		$217K Sell
23,270
-575
-2% -$5K ﹤0.01% 961
2025
Q4 		$175K Buy
+23,845
New +$242K ﹤0.01% 1039
2025
Q2 		– Sell
-30,605
Closed -$98.9K – 1627
2025
Q1 		$98.9K Buy
30,605
+2,564
+9% +$12.1K ﹤0.01% 1027
2024
Q4 		$166K Buy
28,041
+17,576
+168% +$138K ﹤0.01% 1017
2024
Q3 		$113K Sell
10,465
-983
-9% -$16.3K ﹤0.01% 1018
2024
Q2 		$240K Sell
11,448
-7,519
-40% -$189K ﹤0.01% 943
2024
Q1 		$604K Sell
18,967
-868
-4% -$22.1K ﹤0.01% 852
2023
Q4 		$400K Buy
19,835
+4,557
+30% +$60K ﹤0.01% 945
2023
Q3 		$194K Buy
15,278
+820
+6% +$13.7K ﹤0.01% 1025
2023
Q2 		$261K Buy
14,458
+2,422
+20% +$44.6K ﹤0.01% 1004
2023
Q1 		$207K Hold
12,036
– – ﹤0.01% 1024
2022
Q4 		$248K Buy
+12,036
New +$186K ﹤0.01% 1001
2022
Q2 		– Sell
-13,443
Closed -$203K – 1164
2022
Q1 		$203K Buy
13,443
+905
+7% +$14.2K ﹤0.01% 1054
2021
Q4 		$284K Buy
+12,538
New +$307K ﹤0.01% 1021

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Mitsubishi UFJ Asset Management's FDMT Position: Q2 2026 in Review

Mitsubishi UFJ Asset Management increased its 4D Molecular Therapeutics (FDMT) stake by 14% in Q2 2026, buying an estimated $32.9K and bringing the position to 26,644 shares worth $354K. The position accounts for ﹤0.01% of the portfolio, ranked #935.

Mitsubishi UFJ Asset Management first reported a position in FDMT in Q4 2021 and has held it in 15 quarters since. The position peaked at $604K in Q1 2024. 157 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Mitsubishi UFJ Asset Management held 26,644 shares of 4D Molecular Therapeutics worth $354K as of Q2 2026.
  • Mitsubishi UFJ Asset Management bought 3,374 4D Molecular Therapeutics shares in Q2 2026, an estimated $32.9K.
  • 4D Molecular Therapeutics made up ﹤0.01% of Mitsubishi UFJ Asset Management's portfolio in Q2 2026, its #935 holding.
  • Mitsubishi UFJ Asset Management first reported a position in 4D Molecular Therapeutics in Q4 2021 and has held it in 15 quarters since.
  • Mitsubishi UFJ Asset Management's 4D Molecular Therapeutics position peaked at $604K in Q1 2024.
  • 157 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Mitsubishi UFJ Asset Management's 13F filing for Q2 2026, filed 7 Aug 2026.